A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
about
Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agentsDynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin.Cardiovascular toxicity profiles of vascular-disrupting agents.Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrestSynthesis and biological evaluation of 2-substituted-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents.Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agentsSmall Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.An overview of tubulin inhibitors that interact with the colchicine binding siteDesign, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.Concise synthesis and biological evaluation of 2-Aroyl-5-amino benzo[b]thiophene derivatives as a novel class of potent antimitotic agents.Combretastatin A4 phosphate: a novel vascular disrupting agent.Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.Fosbretabulin for the treatment of anaplastic thyroid cancer.Combretastatin A4-phosphate and its potential in veterinary oncology: a review.Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential.Synthesis, biological evaluation, and structure-activity relationships of tri- and tetrasubstituted olefins related to isocombretastatin A-4 as new tubulin inhibitors.Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy.3-substituted 2-phenylimidazo[2,1-b]benzothiazoles: synthesis, anticancer activity, and inhibition of tubulin polymerization.Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.Nitroxides as Antioxidants and Anticancer Drugs.Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data integration.Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.Combined Molecular Docking, 3D-QSAR, and Pharmacophore Model: Design of Novel Tubulin Polymerization Inhibitors by Binding to Colchicine-binding Site.Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: in vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy.Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
P2860
Q31024172-1E3D1090-A060-4864-8C61-3C983BEB8C48Q33393879-2590559D-F6A6-4EDD-AC6A-FCC7E952D4CDQ34094154-72E2E7C3-1503-45CD-BDFD-4528AF7EB520Q34155028-A7767AB3-024E-4301-887C-994FA0CD0DF7Q34240999-E0F122D4-0BDB-4EBD-8B69-419D0998D567Q35077659-2CA798B6-820D-48EB-8B08-E59E8663E20EQ35264818-4B0A2648-434C-4383-B3EF-9760A12A0AE3Q35532093-C7696CB7-BC62-4A8E-8A6E-9B79189AD9A4Q35584746-03F12CA4-42B8-41A0-BFB2-724A6B8A8F36Q35855949-98D8E0F3-4B2C-4A97-A4A7-9839C92E5E19Q36295196-DCA6D866-5C6E-4A2F-B106-EDF9E829A96FQ36503104-75D24DE7-2A4A-4648-BDB4-2B2AC3578219Q36584907-6DA0E2D9-A33A-4FB5-A562-77C5E1F095D4Q36609881-8EB78BC1-4B88-4523-BAA4-2A5955F79FE0Q36613314-C40A083F-C91B-4148-9A22-FFA6D8877C3DQ36756648-3B0DDF29-3FD7-4506-A2D1-0DC2EAA29B0DQ36885540-5892D8DC-6A59-4DFE-A3E3-594740214808Q37284843-50FE04B6-16CA-4FD4-BB0C-8B79607FF2D2Q37474683-CF95D8A0-BE2D-4F9B-BC77-73165E95E0EEQ37507733-505FB9AA-320D-4816-BA05-BA0E692DFC5AQ37783616-56833FEB-41F5-40A6-801C-444E2E6F547BQ37979314-6FC00184-37B9-4E8D-B84E-FEEFED8ED117Q38268163-675D3B9B-7CF3-4801-ABE0-70905A85F63AQ38490875-FC4D3E36-D2FB-4F50-87EC-334C2FAD6148Q39013723-1F8E6751-A217-44BE-92A1-84A82F2D4E35Q39263355-318AABFA-6106-4FC2-9DC9-3633D3C33C01Q39412065-303CF649-E65C-492D-A324-C7DF277F0FD9Q39412957-939AF482-FF38-4665-8293-155EFBABBABFQ39512017-173919A7-1801-4FA8-8887-CC1240843EEEQ47121511-6A2EB3A0-2BEA-491D-84DB-6FCD1B180592Q47133279-593F79CA-B5BE-44D2-8FFC-EE90E1CBE87FQ47948941-0D22AC74-A975-4E0A-B54B-13F2C605AF78Q49244147-BC105AF7-8F62-4504-9B46-282FC66DC1D9Q49302678-43307D18-DABE-4074-BB07-BF8D1E234B64Q51005161-C4EBAC25-3F53-4866-94B4-EFFB4F55031CQ52656539-4F555986-E9D8-4BA2-9DD5-35E14B3C1EB4Q52663446-ADEADD64-60FF-407E-A22C-A44D14AB64F9Q55365628-3697305E-8666-46BC-83C5-636C9693604D
P2860
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A Phase Ib trial of CA4P (comb ...... patients with advanced cancer.
@ast
A Phase Ib trial of CA4P (comb ...... patients with advanced cancer.
@en
type
label
A Phase Ib trial of CA4P (comb ...... patients with advanced cancer.
@ast
A Phase Ib trial of CA4P (comb ...... patients with advanced cancer.
@en
prefLabel
A Phase Ib trial of CA4P (comb ...... patients with advanced cancer.
@ast
A Phase Ib trial of CA4P (comb ...... patients with advanced cancer.
@en
P2093
P2860
P356
P1476
A Phase Ib trial of CA4P (comb ...... patients with advanced cancer.
@en
P2093
D J Chaplin
G J Rustin
G Shreeves
J Balkissoon
M R L Stratford
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605650
P407
P577
2010-04-13T00:00:00Z
P5875
P6179
1018939488